S&P 500   4,288.34 (+1.59%)
DOW   33,795.67 (+2.22%)
QQQ   355.02 (+0.86%)
AAPL   180.70 (+0.34%)
MSFT   336.36 (+1.14%)
META   273.74 (+0.41%)
GOOGL   125.04 (+1.07%)
AMZN   124.76 (+1.62%)
TSLA   216.06 (+4.12%)
NVDA   393.25 (-1.12%)
NIO   7.64 (+1.33%)
BABA   84.68 (+2.02%)
AMD   118.24 (-1.03%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.35 (+0.38%)
CGC   0.82 (-2.07%)
GE   106.56 (+1.81%)
DIS   91.03 (+2.75%)
AMC   4.57 (+0.44%)
PFE   38.53 (+1.34%)
PYPL   64.11 (+1.68%)
NFLX   402.37 (-0.19%)
S&P 500   4,288.34 (+1.59%)
DOW   33,795.67 (+2.22%)
QQQ   355.02 (+0.86%)
AAPL   180.70 (+0.34%)
MSFT   336.36 (+1.14%)
META   273.74 (+0.41%)
GOOGL   125.04 (+1.07%)
AMZN   124.76 (+1.62%)
TSLA   216.06 (+4.12%)
NVDA   393.25 (-1.12%)
NIO   7.64 (+1.33%)
BABA   84.68 (+2.02%)
AMD   118.24 (-1.03%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.35 (+0.38%)
CGC   0.82 (-2.07%)
GE   106.56 (+1.81%)
DIS   91.03 (+2.75%)
AMC   4.57 (+0.44%)
PFE   38.53 (+1.34%)
PYPL   64.11 (+1.68%)
NFLX   402.37 (-0.19%)
S&P 500   4,288.34 (+1.59%)
DOW   33,795.67 (+2.22%)
QQQ   355.02 (+0.86%)
AAPL   180.70 (+0.34%)
MSFT   336.36 (+1.14%)
META   273.74 (+0.41%)
GOOGL   125.04 (+1.07%)
AMZN   124.76 (+1.62%)
TSLA   216.06 (+4.12%)
NVDA   393.25 (-1.12%)
NIO   7.64 (+1.33%)
BABA   84.68 (+2.02%)
AMD   118.24 (-1.03%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.35 (+0.38%)
CGC   0.82 (-2.07%)
GE   106.56 (+1.81%)
DIS   91.03 (+2.75%)
AMC   4.57 (+0.44%)
PFE   38.53 (+1.34%)
PYPL   64.11 (+1.68%)
NFLX   402.37 (-0.19%)
S&P 500   4,288.34 (+1.59%)
DOW   33,795.67 (+2.22%)
QQQ   355.02 (+0.86%)
AAPL   180.70 (+0.34%)
MSFT   336.36 (+1.14%)
META   273.74 (+0.41%)
GOOGL   125.04 (+1.07%)
AMZN   124.76 (+1.62%)
TSLA   216.06 (+4.12%)
NVDA   393.25 (-1.12%)
NIO   7.64 (+1.33%)
BABA   84.68 (+2.02%)
AMD   118.24 (-1.03%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.35 (+0.38%)
CGC   0.82 (-2.07%)
GE   106.56 (+1.81%)
DIS   91.03 (+2.75%)
AMC   4.57 (+0.44%)
PFE   38.53 (+1.34%)
PYPL   64.11 (+1.68%)
NFLX   402.37 (-0.19%)
NASDAQ:BLRX

BioLineRx (BLRX) Stock Forecast, Price & News

$1.66
+0.04 (+2.43%)
(As of 02:29 PM ET)
Compare
Today's Range
$1.59
$1.68
50-Day Range
$0.79
$1.65
52-Week Range
$0.55
$1.98
Volume
173,742 shs
Average Volume
402,673 shs
Market Capitalization
$102.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

BioLineRx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
270.4% Upside
$6.00 Price Target
Short Interest
Bearish
3.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-1.17mentions of BioLineRx in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.69) to ($0.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

832nd out of 983 stocks

Pharmaceutical Preparations Industry

416th out of 486 stocks


BLRX stock logo

About BioLineRx (NASDAQ:BLRX) Stock

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Stock News Headlines

The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
biolinerx Q1 2023 Earnings Preview
BioLine RX Ltd (BLRX)
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
BioLineRx (NASDAQ:BLRX) Given "Buy" Rating at HC Wainwright
H.C. Wainwright Remains a Buy on Bioline RX Ltd Sponsored ADR (BLRX)
BLRX: Confidence in a Strong Launch
BioLineRx Ltd. (BLRX.TA)
See More Headlines

BLRX Price History

BLRX Company Calendar

Last Earnings
3/22/2023
Today
6/02/2023
Next Earnings (Estimated)
8/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLRX
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+270.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.64 per share

Miscellaneous

Free Float
60,854,000
Market Cap
$99.68 million
Optionable
Not Optionable
Beta
1.89

Key Executives

  • Philip Adam Serlin
    Chief Executive Officer
  • Mali Zeevi
    Chief Financial Officer
  • Irit Gliko-Kabir
    Vice President-Clinical Operations
  • Tami Rachmilewitz
    Chief Medical Officer
  • Ella Sorani
    Chief Development Officer













BLRX Stock - Frequently Asked Questions

Should I buy or sell BioLineRx stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLRX shares.
View BLRX analyst ratings
or view top-rated stocks.

What is BioLineRx's stock price forecast for 2023?

1 Wall Street research analysts have issued twelve-month price objectives for BioLineRx's stock. Their BLRX share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 270.4% from the stock's current price.
View analysts price targets for BLRX
or view top-rated stocks among Wall Street analysts.

How have BLRX shares performed in 2023?

BioLineRx's stock was trading at $0.59 at the beginning of the year. Since then, BLRX stock has increased by 174.6% and is now trading at $1.62.
View the best growth stocks for 2023 here
.

Are investors shorting BioLineRx?

BioLineRx saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,950,000 shares, an increase of 69.6% from the April 30th total of 1,150,000 shares. Based on an average daily volume of 489,900 shares, the days-to-cover ratio is presently 4.0 days.
View BioLineRx's Short Interest
.

When is BioLineRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 15th 2023.
View our BLRX earnings forecast
.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) announced its quarterly earnings data on Wednesday, March, 22nd. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05.

What other stocks do shareholders of BioLineRx own?
What is BioLineRx's stock symbol?

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

Who are BioLineRx's major shareholders?

BioLineRx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Altium Capital Management LP (3.70%), Renaissance Technologies LLC (0.17%) and Envestnet Asset Management Inc. (0.16%).

How do I buy shares of BioLineRx?

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLineRx's stock price today?

One share of BLRX stock can currently be purchased for approximately $1.62.

How much money does BioLineRx make?

BioLineRx (NASDAQ:BLRX) has a market capitalization of $99.68 million. The biotechnology company earns $-24,950,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How can I contact BioLineRx?

BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The official website for the company is www.biolinerx.com. The biotechnology company can be reached via phone at (728) 642-9100, via email at ir@biolinerx.com, or via fax at 972-8642-9101.

This page (NASDAQ:BLRX) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -